In the complex tapestry of leadership, awareness isn’t just a desirable trait; it’s the bedrock upon which success is built. It’s the lens through which leaders perceive, interpret, and navigate the ever-shifting landscape of their organizations and industries. Without it,…
REGULATORY
MHLW Orders Label Revisions for Lixiana, Keytruda, and More Drugs
The Ministry of Health, Labor and Welfare (MHLW) on January 29 ordered safety-related label revisions for a batch of medicines, including MSD’s PD-1 inhibitor Keytruda (pembrolizumab) and Daiichi Sankyo’s anticoagulant Lixiana (edoxaban). The label of Keytruda will newly add pancreatic…
To read the full story
Related Article
- PMDA Reviewing Safety Risks for Joyclu, Lixiana, Keytruda
January 7, 2025
- Blue Letter Issued to OA Drug Joyclu after Anaphylaxis Reports
June 2, 2021
REGULATORY
- Japan Launches Growth Strategy Council, Sets Drug Discovery as Priority Field
November 5, 2025
- MHLW Clarifies When Generic Drug Mergers Must Be Reviewed by Antitrust Regulator
November 5, 2025
- LDP Project Team Urges Economic Measures Reflecting Price Pressures
November 4, 2025
- Former Flagship Brands among 506 Drugs Set for Delisting
November 4, 2025
- Anticoagulants and Other Drugs under PMDA Safety Review
November 4, 2025
Japan’s Ministry of Health, Labor and Welfare (MHLW) proposed a full review of the so-called “G1/G2” rule — a framework…
Japan’s drug wholesalers are facing mounting financial pressure as rising logistics and procurement costs deepen losses on product distribution, even…
Japan’s Central Social Insurance Medical Council (Chuikyo) on October 15 approved the reimbursement listing of five new medicines, with the…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…